| Megan Dreesen, | |
|
525 W Cherry St, Vermillion, SD 57069-1141 | |
| (605) 624-9591 | |
| Not Available |
| Full Name | Megan Dreesen |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 525 W Cherry St, Vermillion, South Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780219634 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 5721 (South Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Megan Dreesen, 525 W Cherry St, Vermillion, SD 57069-1141 Ph: (605) 624-9591 | Megan Dreesen, 525 W Cherry St, Vermillion, SD 57069-1141 Ph: (605) 624-9591 |
News Archive
Patients with double hit lymphoma (DHL) who undergo autologous stem-cell transplantation (autoSCT) after achieving remission are not more likely to remain in remission or live longer than patients who do not undergo autoSCT, according to a new analysis from the Perelman School of Medicine and the Abramson Cancer Center of the University of Pennsylvania.
NextGen Healthcare Information Systems, Inc., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare and connectivity solutions, today commented that the Notice of Proposed Rule Making issued last week on electronic health record (EHR) incentive programs moves the healthcare industry closer to securing American Recovery and Reinvestment Act (ARRA) stimulus payments for healthcare IT adoption.
Prophylactic salpingo-oophorectomy-removal of the ovaries and fallopian tubes-reduces the relative risk of breast cancer by approximately 50 percent and the risk of ovarian and fallopian tube cancer by approximately 80 percent in women who carry a mutation in the BRCA1 or BRCA2 gene, researchers report in the January 13 online issue of the Journal of the National Cancer Institute.
Kamada, a biopharmaceutical company developing, manufacturing and marketing specialty life-saving therapeutics, announced today it has received an Israeli Patent for its Ultrapure Transferrin to be used in Pharmaceutical Compositions.
A component of the human interferon system that activates SARS-CoV-2 cellular defenses appears to be defective in a proportion of humans, new research reports. COVID-19 outcomes were more severe in hospitalized patients who exhibited this immune system deficit, the study shows.
› Verified 4 days ago
Susan Mary Burbach, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 525 W Cherry St, Vermillion, SD 57069 Phone: 605-624-9591 | |
Mr. Steven J. Heirigs, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 525 W Cherry St, Hy-vee Pharmacy, Vermillion, SD 57069 Phone: 605-624-9591 Fax: 605-924-9593 | |
Kylie Ann Brooks, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1207 Princeton Ave, Vermillion, SD 57069 Phone: 605-624-4106 Fax: 605-624-4139 | |
Zachary Hunter Birchem, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1207 Princeton Ave, Vermillion, SD 57069 Phone: 605-624-4106 | |
Matthew Lavin, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 20 S Plum St, Vermillion, SD 57069 Phone: 605-638-8455 | |
Vertus Anderson, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1207 Princeton Ave, Vermillion, SD 57069 Phone: 605-624-4106 Fax: 605-624-4139 |